Status:

COMPLETED

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity

Lead Sponsor:

Tonghua Dongbao Pharmaceutical Co.,Ltd

Conditions:

Obesity

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with obesity. This study includes three multiple-ascending dose c...

Eligibility Criteria

Inclusion

  • Age between 18 and 65 years (inclusive), male or female;
  • Body mass index (BMI) ≥ 28 kg/m²;
  • Diet and exercise control for at least 3 months before screening visit, and less than 5% self-reported change within the last 3 months.

Exclusion

  • Type 1 diabetes, type 2 diabetes, gestational diabetes, or other types of diabetes;
  • History of obesity attributable to endocrine diseases, monogenic mutations, or drug-induced causes, such as hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism; or weight gain resulting from increased non-fat mass (e.g., edema);
  • Presence of uncontrolled hypertension at screening: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
  • Prolonged QTcF interval on 12-lead ECG at screening (QTcF≥450 ms for males, \>470 ms for females), PR interval \>200 ms, or the presence of long QT syndrome, second- or third-degree atrioventricular block, left or right bundle branch block, Wolff-Parkinson-White syndrome, or any other clinically significant arrhythmias (except sinus arrhythmia).

Key Trial Info

Start Date :

July 18 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 23 2024

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT06951945

Start Date

July 18 2024

End Date

December 23 2024

Last Update

April 30 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

The First Affiliated Hospital of Bengbu Medical University

Anhui, China

2

Hangzhou First People's Hospital

Zhejiang, China